OptimizeRx (OPRX) – Investment Analysts’ Recent Ratings Changes

OptimizeRx (NASDAQ: OPRX) recently received a number of ratings updates from brokerages and research firms:

• 5/16/2026 – OptimizeRx was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 5/14/2026 – OptimizeRx was downgraded by Weiss Ratings from “sell (d+)” to “sell (d)”.
• 5/13/2026 – OptimizeRx was given a new $10.00 price target by UBS Group AG.
• 5/13/2026 – OptimizeRx had its price target lowered by Lake Street Capital from $20.00 to $11.00. They now have a “buy” rating on the stock.
• 5/13/2026 – OptimizeRx had its price target lowered by Stephens from $10.00 to $7.00. They now have an “equal weight” rating on the stock.
• 5/13/2026 – OptimizeRx had its price target lowered by Stifel Nicolaus from $17.00 to $14.00. They now have a “buy” rating on the stock.
• 5/13/2026 – OptimizeRx had its price target lowered by B. Riley Financial, Inc. from $11.00 to $10.00. They now have a “buy” rating on the stock.
• 5/4/2026 – OptimizeRx was downgraded by Zacks Research from “strong-buy” to “hold”.

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.